XML 56 R45.htm IDEA: XBRL DOCUMENT v3.25.3
Stock-Based Compensation - Stock Option Activity (Details) - Employee Stock Option - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2025
Dec. 31, 2024
Shares    
Options outstanding at beginning of the period 7,540,109  
Granted 1,978,750  
Exercised (50,732)  
Canceled (289,955)  
Options outstanding at the end of the period 9,178,172 7,540,109
Options vested and expected to vest at the end of the period 9,029,315  
Options exercisable at the end of the period 5,130,433  
Shares available for grant under the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended, effective as of June 5, 2025) at September 30, 2025 2,683,538  
Weighted Average Exercise Price Per Share    
Options outstanding at beginning of the period $ 31.47  
Granted 19.59  
Exercised 12.49  
Canceled 111.23  
Options outstanding at the end of the period 26.5 $ 31.47
Options vested and expected to Vest at the end of the period 26.5  
Options exercisable at the end of the period $ 25.85  
Weighted Average Remaining Contractual Term (In Years)    
Options outstanding at the beginning of the period 7 years 3 months 18 days 7 years 6 months
Options vested and expected to vest at the end of the period 7 years 3 months 18 days  
Options exercisable at the end of the period 6 years 1 month 6 days